Keywords: connaught, gp160, vaccine, phase, connaught/pasteur, merieux, serums

CONNAUGHT'S GP160 VACCINE IN PHASE I

Article | 05 July 1993

Print This

Connaught/Pasteur Merieux Serums et Vaccins' live recombinant canarypox-gp160 MN vaccine candidate is to enter Phase I trials in the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in